On February 24, 2014 DNAtrix was awarded a product development grant for $10.8 million to fund the company’s clinical-stage program in glioblastoma (Press release DNAtrix, FEB 24, 2014, View Source [SID:1234500126]). The grant from the Cancer Prevention and Research Institute of Texas (CPRIT) is entitled "Clinical development and commercialization of oncolytic adenovirus for treating malignant glioma."
The grant awarded to DNAtrix will be used to drive the clinical development of DNX-2401, the lead product candidate that is currently undergoing a Phase Ib trial in combination with temozolomide for recurrent glioblastoma. DNX-2401 uses a genetically modified adenovirus that kills tumor cells selectively. In an earlier Phase I study in recurrent glioblastoma, DNX-2401 demonstrated an excellent safety profile and promising efficacy results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!